Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients (CISEVOB)

University Hospital, Clermont-Ferrand

Status and phase: Completed; Phase 2

Conditions: Obesity

Treatments: Drug: Sedation with sevoflurane during 48-hr in ICU

Study type: Interventional

Funder types: Other

Identifiers

NCT02042612

CHU-0176

2010-020044-35

Details and patient eligibility

About

Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients

Full description

Prospective clinical monocentric study in ICU with sedated ventilated obese patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line BMI >30

Exclusion criteria

• Acute kidney injury BMI <30 Sevoflurane anaphylaxia

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

sevoflurane

Experimental group

Description:

Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients

Treatment:

Drug: Sedation with sevoflurane during 48-hr in ICU